NICE recommends Alexion’s long-acting Ultomiris for PNHNICE has recommended Alexion’s long-acting Ultomiris (ravulizumab) for the rare disease paroxysmal nocturnal haemoglobinuria (PNH) in final draft Share XNICE recommends Alexion’s long-acting Ultomiris for PNHhttps://pharmaphorum.com/news/nice-recommends-alexions-long-acting-ultomiris-for-pnh/
NICE backs Sobi’s Kineret for rare inflammatory diseaseThe UK’s cost-effectiveness agency NICE has recommended that Sobi’s Kineret can be used to treat NHS patients with Share XNICE backs Sobi’s Kineret for rare inflammatory diseasehttps://pharmaphorum.com/news/nice-backs-sobis-kineret-for-rare-inflammatory-disease/
NICE methods and process review aims to create fertile ground for innovationThe way NICE reviews new medicines is about to go through its biggest change in years – but Share XNICE methods and process review aims to create fertile ground for innovationhttps://pharmaphorum.com/views-and-analysis/nice-methods-and-process-review-aims-to-create-fertile-ground-for-innovation/
NICE backs ovarian cancer and multiple myeloma combination drugsNICE has recommended funding for two cancer drug combinations for ovarian cancer and multiple myeloma. In final draft Share XNICE backs ovarian cancer and multiple myeloma combination drugshttps://pharmaphorum.com/news/nice-backs-ovarian-cancer-and-multiple-myeloma-combination-drugs/
NICE axes funding for MSD’s Keytruda in bladder cancer despite appealNICE has axed funding for MSD’s Keytruda for second-line advanced bladder cancer in final guidance, despite an appeal Share XNICE axes funding for MSD’s Keytruda in bladder cancer despite appealhttps://pharmaphorum.com/news/nice-axes-funding-for-msds-keytruda-in-bladder-cancer-despite-appeal/
NICE backs AZ’s Calquence for new use in leukaemiaAstraZeneca’s BTK inhibitor Calquence has become the first targeted oral therapy to be backed by NICE for NHS Share XNICE backs AZ’s Calquence for new use in leukaemiahttps://pharmaphorum.com/news/nice-backs-azs-calquence-for-new-use-in-leukaemia/
NICE says NHS should fund Novartis’ £1.79m SMA gene therapyThe NHS should pay for Novartis’ £1.79 million one-off gene therapy for Spinal Muscular Atrophy (SMA) NICE has Share XNICE says NHS should fund Novartis’ £1.79m SMA gene therapyhttps://pharmaphorum.com/news/nice-says-nhs-should-fund-novartis-1-79m-sma-gene-therapy/
NICE says no to AZ’s Lynparza for prostate cancerNHS patients in England will not be able to get access to AstraZeneca’s PARP inhibitor Lynparza if they Share XNICE says no to AZ’s Lynparza for prostate cancerhttps://pharmaphorum.com/news/nice-says-no-to-azs-lynparza-for-prostate-cancer/
Lilly’s Olumiant is first JAK drug backed by NICE for eczemaEli Lilly’s JAK inhibitor Olumiant has become the first drug in the JAK inhibitor class to be recommended Share XLilly’s Olumiant is first JAK drug backed by NICE for eczemahttps://pharmaphorum.com/news/lillys-olumiant-is-first-jak-drug-backed-by-nice-for-eczema/
